Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells 12,236 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 12,236 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.60, for a total transaction of $44,049.60. Following the completion of the transaction, the chief executive officer now directly owns 5,713,197 shares in the company, valued at $20,567,509.20. The trade was a 0.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sight Sciences Trading Down 2.6 %

SGHT traded down $0.09 on Monday, hitting $3.40. 235,749 shares of the company were exchanged, compared to its average volume of 240,716. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The firm has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $5.60. The stock has a market capitalization of $172.57 million, a PE ratio of -3.33 and a beta of 2.57. Sight Sciences, Inc. has a 12 month low of $3.30 and a 12 month high of $8.45.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. Sell-side analysts expect that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. UBS Group started coverage on Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 price objective on the stock. Citigroup dropped their target price on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Lake Street Capital cut shares of Sight Sciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $10.00 to $5.00 in a research report on Monday, November 4th. Finally, Morgan Stanley lowered their price objective on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.12.

Institutional Trading of Sight Sciences

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in Sight Sciences during the 3rd quarter valued at $75,000. The Manufacturers Life Insurance Company bought a new stake in shares of Sight Sciences in the 2nd quarter worth approximately $95,000. GSA Capital Partners LLP purchased a new stake in shares of Sight Sciences in the 3rd quarter worth approximately $136,000. American Century Companies Inc. increased its position in Sight Sciences by 31.1% during the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after buying an additional 8,527 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Sight Sciences by 40.1% during the second quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock valued at $272,000 after acquiring an additional 11,671 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.